Literature DB >> 26103126

Plasma copeptin levels and ambulatory blood pressure characteristics in healthy adults.

Tobias Schoen1, Eva-Maria Hohmann, Stephanie Van Der Lely, Stefanie Aeschbacher, Andreas Reusser, Martin Risch, Lorenz Risch, David Conen.   

Abstract

OBJECTIVE: We investigated whether copeptin - a well characterized vasopressin-related stress hormone - is associated with circadian ambulatory blood pressure (BP) variability and/or mean BP levels in young adults. METHOD AND
RESULTS: We studied a population-based sample of healthy adults aged 25-41 years. Individuals with diabetes, treated hypertension, and cardiovascular disease were excluded. Ambulatory 24-h BP monitoring was performed using validated devices. To evaluate the relationships of copeptin with mean ambulatory BP levels and BP variability during daytime and night-time, multivariable adjusted regression models were constructed. BP variability was defined as SD of all intraindividual BP values. Of the 2012 individuals included in this study, 53% were women and the median age was 37 years. Median plasma copeptin levels were 3.9 (interquartile range 2.7, 5.8) in men and 2.3 pmol/l (interquartile range 1.6, 3.6) in women (P < 0.0001). In multivariable linear regression models, log-transformed copeptin was significantly associated with systolic and diastolic night-time BP levels among men [β = 1.9, 95% confidence interval (CI) 0.6, 3.1, P = 0.003; and β = 1.4, 95% CI 0.6, 2.3, P = 0.001, respectively], but not among women. In addition, copeptin was strongly associated with an increased systolic and diastolic daytime (β = 0.5, 95% CI 0.2, 0.7, P = 0.001; β = 0.5, 95% CI 0.3, 0.8, P < 0.0001, respectively) and night-time BP variability (β = 0.6, 95% CI 0.3, 0.9, P = 0.0002; β = 0.4, 95% CI 0.2, 0.7, P = 0.002, respectively).
CONCLUSION: In this large population-based study of young and healthy adults, plasma levels of copeptin were significantly associated with an increased BP variability in both sexes and an elevated night-time BP among men.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26103126     DOI: 10.1097/HJH.0000000000000610

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  6 in total

Review 1.  The role of copeptin in kidney disease.

Authors:  Pedro Iglesias; Ramona A Silvestre; María José Fernández-Reyes; Juan J Díez
Journal:  Endocrine       Date:  2022-10-15       Impact factor: 3.925

Review 2.  Copeptin as a Diagnostic and Prognostic Biomarker in Cardiovascular Diseases.

Authors:  Danni Mu; Jin Cheng; Ling Qiu; Xinqi Cheng
Journal:  Front Cardiovasc Med       Date:  2022-07-04

3.  Acute effects of salt on blood pressure are mediated by serum osmolality.

Authors:  Mehmet Kanbay; Gamze Aslan; Baris Afsar; Tuncay Dagel; Dimitrie Siriopol; Masanari Kuwabara; Said Incir; Volkan Camkiran; Bernardo Rodriguez-Iturbe; Miguel A Lanaspa; Adrian Covic; Richard J Johnson
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-09-19       Impact factor: 3.738

Review 4.  Pathophysiology of copeptin in kidney disease and hypertension.

Authors:  Baris Afsar
Journal:  Clin Hypertens       Date:  2017-06-13

5.  Effect of Chronic Kidney Disease on Changes in Vasopressin System Expression in the Kidney Cortex in Rats with Nephrectomy.

Authors:  Katarzyna Czarzasta; Agnieszka Cudnoch-Jedrzejewska; Longin Niemczyk; Robert Wrzesien; Marzanna Tkaczyk; Liana Puchalska; Marek Saracyn; Wawrzyniec Zmudzki; Stanisław Niemczyk
Journal:  Biomed Res Int       Date:  2018-06-14       Impact factor: 3.411

Review 6.  Salt, water and nephron: Mechanisms of action and link to hypertension and chronic kidney disease.

Authors:  Qi Qian
Journal:  Nephrology (Carlton)       Date:  2018-10       Impact factor: 2.506

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.